title: Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
abstract: OBJECTIVE
  Detrusor hyperreflexia with elevated storage pressures presents a major risk factor for renal damage in patients with neurogenic lower urinary tract dysfunction. If standard anticholinergic treatment is unsuccessful, surgical treatment must be considered. We evaluated the effects of intravesical oxybutynin treatment on detrusor hyperreflexia in patients in whom standard oral treatment had failed.
  
  
  METHODS
  Twenty-five patients (mean age 36. 7 years) with storage pressures greater than 40 cm H(2)O despite standard anticholinergic treatment received intravesical (15 mg three times daily) and oral oxybutynin chloride treatment. The follow-up evaluations included urodynamic testing, renal ultrasound, urine examination (urinalysis and urine culture), and evaluation of side effects.
  
  
  RESULTS
  The mean follow-up was 6 months. Intravesical treatment led to an increase in bladder storage volume from 349 to 420 mL. The mean maximum storage pressure was significantly reduced from 54 to 26.5 cm H(2)O. Detrusor storage pressures returned to values less than 40 cm H(2)O in 21 of 25 patients. Dysreflexia was treated successfully in 3 of 5 patients. No patient developed renal damage. No severe side effects or drug-related discontinuation of treatment were observed.
  
  
  CONCLUSIONS
  Intravesical oxybutynin therapy seems to be a safe and effective treatment option for detrusor hyperreflexia in adults and avoids surgical treatment in most patients. Long-term observations concerning side effects, acceptance, and efficacy are needed.
authors.affiliation: Department of Urology, Ruhr-Universität Bochum, Herne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Pannek
authors.forename: H J
authors.initials: HJ
authors.lastname: Sommerfeld
authors.forename: U
authors.initials: U
authors.lastname: Bötel
authors.forename: T
authors.initials: T
authors.lastname: Senge
mesh_terms: D000283:Administration, Intravesical; D000284:Administration, Oral; D000293:Adolescent; D018680:Cholinergic Antagonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D008875:Middle Aged; D013119:Spinal Cord Injuries / Q000150:complications*; D001743:Urinary Bladder / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics
chemical_list: D018680:Cholinergic Antagonists; D008333:Mandelic Acids; C005419:oxybutynin